Medication info
Crestor 10mg (Rosuvastatin Calcium)

Crestor 10mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Alikko Pharmaceuticals Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201505162 · Approved 2015.07.30 · Insurance code 656003930

Summary

Main use
Treatment of dyslipidemia; slowing the progression of atherosclerosis; prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams once daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal failure: No dose adjustment is necessary in patients with mild to moderate renal failure. Do not administer to patients with severe renal failure. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal failure. 5. Patients with hepatic failure: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.
Children's dosage
Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
Alikko Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia; slowing the progression of atherosclerosis; prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used as an adjunct when diet and exercise alone are not sufficient in managing primary hypercholesterolemia and mixed dyslipidemia. It is also used as an adjunct to dietary measures in patients with homozygous familial hypercholesterolemia. In patients with hypercholesterolemia, it effectively lowers total cholesterol and LDL-cholesterol levels, delaying the progression of atherosclerosis. Particularly, it is used as an adjunct dietary treatment in pediatric patients aged 10 to 17 with heterozygous familial hypercholesterolemia. It is also beneficial for patients with primary dysbetalipoproteinemia and plays a role in reducing the risk of stroke, myocardial infarction, and vascular revascularization procedures in middle-aged and older adults with high cardiovascular risk. In summary, this medication is effectively used to lower the risk of various forms of hypercholesterolemia and cardiovascular diseases.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams once daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal failure: No dose adjustment is necessary in patients with mild to moderate renal failure. Do not administer to patients with severe renal failure. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal failure. 5. Patients with hepatic failure: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Children's dosage

Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy in children under 10 years of age have not been established.

Precautions

This drug should not be administered to certain patients. For example, individuals who are allergic to this medication, those with active liver disease, muscle disorders, or severe renal impairment should not take this drug. Women who are pregnant, breastfeeding, or who may become pregnant should consult a specialist before use and employ appropriate contraception. Additionally, patients at high risk for myopathy or rhabdomyolysis should avoid high-dose therapy, and careful diagnosis and monitoring are needed before use for those with these risk factors. This medication contains lactose and should not be administered to patients with lactose intolerance or related genetic disorders. Patients who consume excessive alcohol or have a history of liver disease should have regular liver function tests, and those with hypothyroidism or nephrotic syndrome should prioritize treatment of the underlying condition. If symptoms such as muscle pain, weakness, fatigue, or fever occur, immediate medical consultation is necessary, and blood tests should be performed to check for muscle damage. This medication may interact with other drugs, especially with certain antivirals, immunosuppressants, and fibrates, so caution is required when used together. Clinical trials and post-market reports indicate that this drug can cause side effects such as liver function abnormalities, muscle-related adverse reactions, gastrointestinal disturbances, and skin rashes, so any abnormalities should be discussed with medical personnel. Avoid using this medication during pregnancy and breastfeeding, and women planning to become pregnant should ensure adequate contraception. There is no specific antidote for overdose, therefore treatment should be symptomatic, and liver function and muscle enzyme levels should be monitored. Dizziness may occur while taking this medication, so caution is required when driving or operating machinery.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated with drug reaction syndrome, drug eruption resembling psoriasis, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, forgetfulness, amnesic syndrome, memory impairment, confusion, ALT elevation, chest pain, muscle cramps, gout, erectile dysfunction, AST elevation, numbness, sensory disturbances, chest discomfort, appetite loss, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius. This helps to maintain the drug's effectiveness over time.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.